Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$13.5 million.

  • Arrowhead Pharmaceuticals' Change in Accured Expenses fell 7554.28% to -$13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $35.7 million, marking a year-over-year increase of 4858.44%. This contributed to the annual value of $41.5 million for FY2025, which is 2920.57% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$13.5 million for Q4 2025, which was down 7554.28% from $33.5 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Change in Accured Expenses high stood at $33.5 million for Q3 2025, and its period low was -$20.1 million during Q1 2023.
  • For the 5-year period, Arrowhead Pharmaceuticals' Change in Accured Expenses averaged around $3.7 million, with its median value being -$5500.0 (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 198504.9% in 2024, then skyrocketed by 645131.26% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Change in Accured Expenses stood at -$2.3 million in 2021, then tumbled by 214.54% to -$7.2 million in 2022, then surged by 105.66% to $408000.0 in 2023, then tumbled by 1985.05% to -$7.7 million in 2024, then tumbled by 75.54% to -$13.5 million in 2025.
  • Its last three reported values are -$13.5 million in Q4 2025, $33.5 million for Q3 2025, and -$11.0 million during Q2 2025.